The phase III VERITAC-2 trial (NCT05654623) is currently evaluating the efficacy and safety of vepdegestrant versus fulvestrant, while VERITAC-3 (NCT05909397) is assessing vepdegestrant plus palbociclib versus letrozole plus palbociclib in patients with ER+/HER2− advanced breast cancer (266, 268, 269, 393). Here, ESR1 is linked to breast carcinoma.